Back to top
more

Humana (HUM)

(Delayed Data from NYSE)

$279.45 USD

279.45
7,041,273

-37.29 (-11.77%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 8% (232 out of 251)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Humana (HUM) Teams Up With DME Entities to Boost Home Solutions

by Zacks Equity Research

These partnerships will equip Humana (HUM) with the means to deploy advanced clinical programs that can reduce hospitalizations for the members.

Here's Why Humana (HUM) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Select Medical (SEM) Q1 Earnings Top on Improving Profitability

by Zacks Equity Research

Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.

Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet

by Zacks Equity Research

The average brokerage recommendation (ABR) for Humana (HUM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.

Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%

by Zacks Equity Research

Tenet Healthcare's (THC) first-quarter 2023 results gain on increased patient volumes. Management presently expects adjusted EPS within $4.92-$6.09 in 2023, up from the prior view of $4.68-$5.85.

Humana (HUM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums

by Zacks Equity Research

Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.

Humana (HUM) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 1.41% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health

by Zacks Equity Research

Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.

Zacks.com featured highlights Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International

by Zacks Equity Research

Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International have been highlighted in this Screen of The Week article.

Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.

Kaibalya Pravo Dey headshot

4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates

by Kaibalya Pravo Dey

Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).

Aparajita Dutta headshot

Buy These 5 Low Leverage Stocks Ahead of Big Earnings Releases

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt as a debt-free stock is almost impossible to find. You may buy MCS, AMK, HUM, REPX and ICFI.

Is a Surprise Coming for Humana (HUM) This Earnings Season?

by Zacks Equity Research

Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?

by Zacks Equity Research

Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.

What's in Store for Molina Healthcare (MOH) in Q1 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.

Humana (HUM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Humana (HUM) closed the most recent trading day at $491.21, moving +0.18% from the previous trading session.

Universal Health (UHS) to Release Q1 Earnings: Factors to Note

by Zacks Equity Research

Universal Health's (UHS) Q1 results are likely to benefit from higher patient volumes and solid demand for behavioral healthcare services. However, increased labor costs might partly offset the results.

Humana (HUM) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Investors Undervaluing Humana (HUM) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Humana (HUM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Humana (HUM) closed at $518.82 in the latest trading session, marking a -0.96% move from the prior day.

UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care

by Zacks Equity Research

UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.

Wall Street Bulls Look Optimistic About Humana (HUM): Should You Buy?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Humana (HUM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?